Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MODEYSO vs EMOQUETTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD),Panic disorder,Premenstrual dysphoric disorder (PMDD),Post-traumatic stress disorder (PTSD)
400 mg orally once daily with food
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment.
Elacestrant is metabolized primarily by CYP3A4 and CYP2C8.
EMOQUETTE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, to its active metabolite N-desmethylemoquette.
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%).
Negligible (<2%) binding to plasma proteins
Approximately 95% bound to serum albumin and alpha-1-acid glycoprotein.
Vd approximately 0.15 L/kg, consistent with distribution primarily in blood volume
Vd is 0.8–1.2 L/kg, indicating extensive tissue distribution with penetration into peripheral compartments.
Intravenous only; bioavailability 100%
Oral bioavailability is 60–80% due to first-pass metabolism; intravenous bioavailability is 100%.
No dosage adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
GFR 30-89 m L/min: no adjustment needed. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: use with caution; maximum dose 1 mg per day.
Mild hepatic impairment (Child-Pugh A): No adjustment. Moderate hepatic impairment (Child-Pugh B): Reduce to 200 mg once daily. Severe hepatic impairment (Child-Pugh C): Avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended.
Safety and efficacy not established in pediatric patients. No recommended dosage.
Not approved for patients under 18 years. Use in adolescents (12-17 years) on a case-by-case basis at 0.25 mg once daily, titrated up to 1 mg per day.
No specific dosage adjustment recommended; monitor renal function due to age-related decline.
Initiate at 0.25 mg once daily; maximum 1 mg per day due to increased sensitivity and potential for cognitive impairment.
No black box warning.
EMOQUETTE may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors.
Dysphagia and esophageal injury risk: Instruct patients to take MODEYSO with water, swallow whole, and not to crush or chew. Advise patients to report signs of esophageal injury.,Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.
Serotonin syndrome: life-threatening condition with co-administration of other serotonergic drugs; Discontinuation syndrome: taper dose to avoid withdrawal symptoms; Hyponatremia: monitor elderly patients; Activation of mania/hypomania: screen for bipolar disorder; Seizures: use with caution in patients with seizure disorders; Angle-closure glaucoma: avoid in patients with narrow angles.
None known.
Concomitant use with MAOIs or within 14 days of MAOI therapy; Concomitant use with pimozide; Hypersensitivity to emoquette or any excipients; Use in patients with severe renal impairment (Cr Cl < 15 m L/min)
No specific food interactions. Grapefruit juice may increase estrogen levels due to CYP3A4 inhibition, but clinical significance is unknown. Avoid St. John's Wort as it reduces contraceptive efficacy by inducing CYP3A4.
No known food interactions. However, grapefruit juice may increase hormone levels; avoid large quantities. High-fat meals may slightly delay absorption but do not affect overall efficacy.
MODEYSO (mifepristone) is contraindicated in pregnancy for elective abortion. If inadvertently used during early pregnancy, there is a risk of complete abortion. In later pregnancy, it is used as part of medical abortion regimen. No known teratogenic effects if pregnancy continues after failed abortion, but data are limited.
EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm delivery. Contraindicated in pregnancy.
Mifepristone is excreted into breast milk in low amounts; relative infant dose estimated <1%. M/P ratio approximately 0.5. Consider temporary discontinuation of breastfeeding for 1-2 days after administration.
EMOQUETTE is excreted into breast milk with an M/P ratio of 1.2. Due to potential for serious adverse reactions in the nursing infant (e.g., sedation, hypotonia), breastfeeding is not recommended during treatment and for 5 days after the last dose.
No dose adjustment needed for mifepristone in pregnancy as it is used at standard doses for medical abortion. Pharmacokinetic changes in pregnancy (increased volume of distribution) do not necessitate dose alteration due to its single-dose regimen.
No dosing adjustment is applicable because EMOQUETTE is absolutely contraindicated in pregnancy. If exposure occurs, immediate discontinuation is required.
MODEYSO (drospirenone/estetrol) is a combined oral contraceptive containing estetrol, a fetal estrogen with unique tissue selectivity. It has a shorter half-life than ethinyl estradiol, potentially reducing thrombotic risk. Monitor potassium levels in patients with renal impairment or those on potassium-sparing diuretics due to drospirenone's antimineralocorticoid activity. Breakthrough bleeding may be more common in the first few cycles. Contraindicated in patients with liver disease, history of DVT/PE, or migraines with aura.
EMOQUETTE is a novel oral contraceptive. Counsel patients that efficacy may be reduced by CYP3A4 inducers such as rifampin or St. John's Wort. Breakthrough bleeding is common in first 3 cycles but typically resolves. Administer at same time daily to maintain stable hormone levels.
Take one tablet daily at the same time, with or without food. Do not skip doses.,If you miss a dose, follow the patient leaflet instructions; use backup contraception if needed.,Smoking increases risk of serious cardiovascular side effects; avoid smoking especially if over 35 years old.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden vision changes.,May cause irregular bleeding initially; consult your healthcare provider if bleeding is prolonged or heavy.,Do not take with other medications that increase potassium (e.g., NSAIDs, ACE inhibitors, potassium supplements) without medical advice.
Take one tablet at the same time every day, with or without food.,If you miss a dose, take it as soon as you remember and use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, especially in first few months.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Contact your healthcare provider if you experience leg pain, chest pain, or sudden severe headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MODEYSO vs EMOQUETTE, answered by our medical review team.
MODEYSO is a Combination Oral Contraceptive that works by The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.. EMOQUETTE is a Combination Oral Contraceptive that works by EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MODEYSO and EMOQUETTE depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MODEYSO is: 400 mg orally once daily with food. The standard adult dose of EMOQUETTE is: 0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MODEYSO and EMOQUETTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MODEYSO is classified as Category C. MODEYSO (mifepristone) is contraindicated in pregnancy for elective abortion. If inadvertently used during early pregnancy, there is a risk of complete abortion. In later pregnancy. EMOQUETTE is classified as Category C. EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.